ICONIK enables real-time review of data, drill-down to explore data and proactively address issues and analysis of site quality metrics and clinical endpoints. This in turn enhances clinical decision making, permits validated adaptive monitoring processes, and drives quality and efficiency throughout the study. But most importantly it helps us to focus on risk management and operational effectiveness rather than spending so much time on resolving problems that can be avoided by better planning and risk management.

What are the disease-related focus areas for ICON in Asia?

ICON provides outsourcing of clinical development across all therapeutic areas in Asia Pacific. Oncology is currently ICON’s fastest-growing therapeutic area in Asia Pacific, with 167 on-going studies at more than 700 sites. The indications mainly include breast, lung, lymphoma/leukemia, gastric, melanoma/myeloma, prostate and solid tumor. We also have extensive experience in conducting clinical trials within disease areas, including cardiovascular, infectious diseases, central nervous system, endocrinology, gastroenterology and hematology across the entire region.

The prevalence of certain diseases in Asia Pacific makes it attractive for patient access in specific therapeutic areas but these can vary from country to country. For example, diabetes is one of these diseases. Our in-depth expertise in this area enables us to deliver excellence in the management of clinical development programmes and we have strong relationships with investigator sites that ensure high rates of patient enrolment and retention.